adenine has been researched along with Herpes Simplex in 27 studies
Herpes Simplex: A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In addition to protecting against HIV acquisition, antiretroviral preexposure prophylaxis (PrEP) using topical 1% tenofovir gel reduced Herpes simplex virus type 2 (HSV-2) acquisition by 51% among women in the CAPRISA 004 study." | 7.80 | Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. ( Casapia, M; Glidden, DV; Grant, RM; Hoagland, B; Lama, JR; Liu, AY; Marcus, JL; Mayer, KH; McMahan, V; Montoya-Herrera, O, 2014) |
| "to determine the impact of oral tenofovir as part of combination antiretroviral therapy on asymptomatic herpes simplex virus (HSV) shedding." | 7.77 | No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. ( Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL, 2011) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "The susceptibility of herpes simplex type 1 and type 2 viruses to 9-beta-d-arabinofuranosyladenine (ara-A) was tested in intracerebrally infected mice." | 7.65 | Treatment of herpes simplex virus types 1 and 2 encephalitis in mice with 9-beta-D-arabinofuranosyladenine. ( McLean, IW; Miller, FA; Sloan, BJ, 1973) |
| " (S)-HPMPA inhibited the development of tail lesions caused by vaccinia virus if it was administered intraperitoneally or subcutaneously at a dosage as low as 5 mg/kg per day." | 5.28 | Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. ( De Clercq, E; Holý, A; Rosenberg, I, 1989) |
| " Tenofovir dipivoxil, a novel ester prodrug of tenofovir, can be used for treatment for hepatitis B and HIV infection and it was necessary to evaluate the effect of its treatment on carnitine homeostasis." | 5.17 | Impact on L-carnitine Homeostasis of Short-term Treatment with the Pivalate Prodrug Tenofovir Dipivoxil. ( Feng, J; Hang, TJ; Jia, YY; Lu, CT; Song, Y; Sun, Y; Wang, S; Wen, AD; Yang, ZF; Zhao, JY, 2013) |
| "In addition to protecting against HIV acquisition, antiretroviral preexposure prophylaxis (PrEP) using topical 1% tenofovir gel reduced Herpes simplex virus type 2 (HSV-2) acquisition by 51% among women in the CAPRISA 004 study." | 3.80 | Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. ( Casapia, M; Glidden, DV; Grant, RM; Hoagland, B; Lama, JR; Liu, AY; Marcus, JL; Mayer, KH; McMahan, V; Montoya-Herrera, O, 2014) |
| "to determine the impact of oral tenofovir as part of combination antiretroviral therapy on asymptomatic herpes simplex virus (HSV) shedding." | 3.77 | No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. ( Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL, 2011) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "The acyclic nucleotide analogue (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl)-adenine [(S)-HPMPA], which contains a phosphonate-substituted aliphatic chain, is a potent and selective inhibitor of the replication of various DNA viruses, including herpes simplex virus type 1 (HSV-1)." | 3.67 | Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. ( Bernaerts, R; De Clercq, E; Holý, A; Merta, A; Rosenberg, I; Sakuma, T; Votruba, I, 1987) |
| "Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice." | 3.66 | Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice. ( Arnett, G; Cohen, SS; North, TW; Schabel, FM; Shannon, WM, 1980) |
| "Three hundred four animals were used for the systematic evaluation of the in vivo efficacy of 5-iodo-2'-deoxyuridine (IUDR), cytosire arabinoside, 9-beta-arabinofuranosyladenine, and isoprinosine in the therapy of herpes simplex encephalitis in an adult rat model." | 3.65 | Evaluation of four antiviral agents in the treatment of herpes simplex encephalitis in a rat model. ( Marks, MI, 1975) |
| "The susceptibility of herpes simplex type 1 and type 2 viruses to 9-beta-d-arabinofuranosyladenine (ara-A) was tested in intracerebrally infected mice." | 3.65 | Treatment of herpes simplex virus types 1 and 2 encephalitis in mice with 9-beta-D-arabinofuranosyladenine. ( McLean, IW; Miller, FA; Sloan, BJ, 1973) |
| "A hairless mouse-herpes simplex virus skin infection experimental model was used to evaluate the efficacy of the antiviral compounds 9-beta-d-arabinofuranosyladenine (ara-A), 5-iodo-2'-deoxyuridine (IUdR), and 6-azauridine (aza-U)." | 3.65 | Herpes simplex virus skin infection in hairless mice: treatment with antiviral compounds. ( Brady, E; Friedman-Kien, AE; Klein, RJ, 1974) |
| "These results indicate that MAIDS can be used as a model for evaluating antivirals in an immunocompromised host, and suggest that both PMEA and HPMPC may be useful in the treatment of opportunistic CMV and HSV-1 infections." | 1.28 | Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. ( De Castro, LM; De Clercq, E; Gangemi, JD; Ghaffar, A; Kern, ER; Mayer, EP; Vogt, PE, 1991) |
| " (S)-HPMPA inhibited the development of tail lesions caused by vaccinia virus if it was administered intraperitoneally or subcutaneously at a dosage as low as 5 mg/kg per day." | 1.28 | Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. ( De Clercq, E; Holý, A; Rosenberg, I, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (74.07) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 3 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, YY | 1 |
| Lu, CT | 1 |
| Feng, J | 1 |
| Song, Y | 1 |
| Zhao, JY | 1 |
| Wang, S | 1 |
| Sun, Y | 1 |
| Wen, AD | 1 |
| Yang, ZF | 1 |
| Hang, TJ | 1 |
| Marcus, JL | 1 |
| Glidden, DV | 1 |
| McMahan, V | 1 |
| Lama, JR | 1 |
| Mayer, KH | 1 |
| Liu, AY | 1 |
| Montoya-Herrera, O | 1 |
| Casapia, M | 1 |
| Hoagland, B | 1 |
| Grant, RM | 1 |
| Tan, DH | 1 |
| Kaul, R | 1 |
| Raboud, JM | 1 |
| Walmsley, SL | 1 |
| Ruiz, JC | 1 |
| Beadle, JR | 1 |
| Aldern, KA | 1 |
| Keith, KA | 1 |
| Hartline, CB | 1 |
| Kern, ER | 2 |
| Hostetler, KY | 1 |
| Andrei, G | 1 |
| Fiten, P | 1 |
| Froeyen, M | 1 |
| De Clercq, E | 6 |
| Opdenakker, G | 1 |
| Snoeck, R | 1 |
| Shannon, WM | 1 |
| Arnett, G | 1 |
| Schabel, FM | 1 |
| North, TW | 1 |
| Cohen, SS | 2 |
| Bestman-Smith, J | 1 |
| Boivin, G | 1 |
| Marks, MI | 1 |
| Brunell, P | 1 |
| De Castro, LM | 1 |
| Ghaffar, A | 1 |
| Mayer, EP | 1 |
| Vogt, PE | 1 |
| Gangemi, JD | 2 |
| Cozens, RM | 1 |
| Balzarini, J | 1 |
| Hochkeppel, HK | 1 |
| Nishiyama, Y | 1 |
| Yamamoto, N | 1 |
| Yamada, Y | 1 |
| Fujioka, H | 1 |
| Shimada, N | 1 |
| Takahashi, K | 1 |
| Holý, A | 2 |
| Rosenberg, I | 2 |
| Votruba, I | 1 |
| Bernaerts, R | 1 |
| Sakuma, T | 1 |
| Merta, A | 1 |
| Kusmierek, JT | 1 |
| Czochralska, B | 1 |
| Johansson, NG | 1 |
| Shugar, D | 1 |
| Weinstein, L | 1 |
| Chang, TW | 1 |
| Miyai, K | 1 |
| Allen, LB | 2 |
| Huffman, JH | 1 |
| Sidwell, RW | 2 |
| Tolman, RL | 1 |
| Brightbill, FS | 1 |
| Kaufman, HE | 2 |
| Light, IJ | 1 |
| Linnemann, CC | 1 |
| Lerner, AM | 1 |
| Lauter, CB | 1 |
| Nolan, DC | 1 |
| Sloan, BJ | 2 |
| Miller, FA | 2 |
| McLean, IW | 1 |
| Klein, RJ | 1 |
| Friedman-Kien, AE | 1 |
| Brady, E | 1 |
| Silverman, CA | 1 |
3 reviews available for adenine and Herpes Simplex
| Article | Year |
|---|---|
Inhibitors of adenosine deaminase and the development of antiviral agents.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Antiviral Agents; Cytarabine; Deoxyadenosines; Dru | 1985 |
Virus-drug resistance: thymidine kinase-deficient (TK-) mutants of herpes simplex virus. Therapeutic approaches.
Topics: Acyclovir; Adenine; Antiviral Agents; Drug Resistance, Microbial; Herpes Simplex; Humans; Organophos | 1987 |
Ocular virus disease.
Topics: Adenine; Adolescent; Chickenpox; Child; Child, Preschool; Chorioretinitis; Conjunctivitis; Corneal U | 1973 |
2 trials available for adenine and Herpes Simplex
| Article | Year |
|---|---|
Impact on L-carnitine Homeostasis of Short-term Treatment with the Pivalate Prodrug Tenofovir Dipivoxil.
Topics: Adenine; Adult; Antiviral Agents; Carnitine; Dose-Response Relationship, Drug; Female; Hepatitis B; | 2013 |
Antiviral drugs for the neonate--the risk-benefit ledger.
Topics: Adenine; Animals; Antiviral Agents; Arabinose; Brain; Brain Diseases; Clinical Trials as Topic; Cyta | 1975 |
22 other studies available for adenine and Herpes Simplex
| Article | Year |
|---|---|
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; H | 2014 |
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Canada; Female; Herpes Simplex; Herpesvirus 1 | 2011 |
Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.
Topics: Adenine; Antiviral Agents; Cell Line; Cidofovir; Cowpox; Cytomegalovirus Infections; Cytosine; Herpe | 2007 |
DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
Topics: Adenine; Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Disease Models, Anima | 2007 |
Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Antiviral Agents; Drug Synergism; Drug Therapy, Co | 1980 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |
Evaluation of four antiviral agents in the treatment of herpes simplex encephalitis in a rat model.
Topics: Acetanilides; Adenine; Animals; Antiviral Agents; Arabinose; Brain; Cell Line; Culture Techniques; C | 1975 |
Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Ganciclovir; He | 1991 |
9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Antiviral Agents; Concanavalin A; Herpes Simpl | 1989 |
Efficacy of oxetanocin G against herpes simplex virus type 2 and murine cytomegalovirus infections in mice.
Topics: Acyclovir; Adenine; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease | 1989 |
Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.
Topics: Adenine; Animals; Antiviral Agents; Brain Diseases; Herpes Simplex; Injections; Injections, Intraper | 1989 |
Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis.
Topics: Adenine; Animals; Antiviral Agents; DNA, Viral; Herpes Simplex; Leukemia L1210; Organophosphonates; | 1987 |
Preparative electrochemical reduction of 2-amino-6-chloropurine and synthesis of 6-deoxyacyclovir, a fluorescent substrate of xanthine oxidase and a prodrug of acyclovir.
Topics: 2-Aminopurine; Acyclovir; Adenine; Animals; Antiviral Agents; Electrolysis; Guinea Pigs; Herpes Simp | 1987 |
The chemotherapy of viral infections.
Topics: Acridines; Adenine; Amantadine; Amino Alcohols; Antiviral Agents; Arabinose; Benzoates; Coloring Age | 1973 |
Synthesis and anti-deoxyribonucleic acid virus activity of certain 9-beta-D-arabinofuranosyl-2-substituted adenine derivatives.
Topics: Adenine; Adenoviridae; Animals; Arabinose; Carcinoma; Cell Line; Cricetinae; Cytopathogenic Effect, | 1974 |
Adenine arabinoside therapy in corneal stromal disease and iritis due to herpes simplex.
Topics: Adenine; Aged; Anterior Chamber; Antiviral Agents; Aqueous Humor; Arabinose; Female; Herpes Simplex; | 1974 |
Neonatal herpes simplex infection following delivery by cesarean section.
Topics: Adenine; Anti-Infective Agents; Arabinose; Cesarean Section; Extraembryonic Membranes; Female; Herpe | 1974 |
Herpes simplex virus encephalitis: therapy trials.
Topics: Adenine; Arabinose; Encephalitis; Herpes Simplex; Humans; Idoxuridine; Nucleosides | 1973 |
Target-organ treatment of neurotropic virus diseases: efficacy as a chemotherapy tool and comparison of activity of adenine arabinoside, cytosine arabinoside, idoxuridine, and trifluorothymidine.
Topics: Adenine; Animals; Antiviral Agents; Arabinose; Brain; Cytarabine; Fluorine; Herpes Simplex; Idoxurid | 1972 |
Treatment of herpes simplex virus types 1 and 2 encephalitis in mice with 9-beta-D-arabinofuranosyladenine.
Topics: Adenine; Animals; Antiviral Agents; Arabinose; Encephalitis; Herpes Simplex; Male; Mice; Mice, Inbre | 1973 |
Herpes simplex virus skin infection in hairless mice: treatment with antiviral compounds.
Topics: Adenine; Animals; Antiviral Agents; Arabinose; Azauridine; Disease Models, Animal; Female; Herpes Si | 1974 |
Antiviral activity of 9-beta-D-arabinofuranosyladenine. VI. Effect of delayed treatment on herpes simplex virus in mice.
Topics: Adenine; Animals; Antiviral Agents; Herpes Simplex; Mice; Nucleosides | 1969 |